降钙素基因相关肽
苏马曲普坦
脑膜
神经源性炎症
三叉神经节
偏头痛
医学
药理学
降钙素
神经肽
三叉神经
兴奋剂
内科学
内分泌学
麻醉
受体
神经科学
P物质
病理
生物
感觉系统
作者
Volker Limmroth,Zaza Katsarava,Bernd Liedert,Hans Guehring,Kerstin Schmitz,Hans‐Christoph Diener,Martin C. Michel
出处
期刊:Pain
[Ovid Technologies (Wolters Kluwer)]
日期:2001-05-01
卷期号:92 (1): 101-106
被引量:67
标识
DOI:10.1016/s0304-3959(00)00475-9
摘要
Calcitonin gene related peptide (CGRP) released from the C-fibers projecting from the trigeminal ganglion to the meninges has been suggested to play a crucial role in the pathophysiology of headache, particularly migraine. In humans it has been shown that CGRP is released during migraine-attacks, and this is attenuated by the administration of typical anti-migraine drugs such as dihydroergotamine or sumatriptan. We describe a new rat model which allows the study of CGRP release from the meninges into venous blood following activation of the trigeminal vascular system. The effects of classical and new anti-migraine drugs such as acetylsalicylic acid (ASA), sumatriptan and the new high efficacy 5-HT1B/1D agonist donitriptan (4-[4-[2-(2-aminoethyl)-1H-indol-5-yloxyl]acetyl]piperazinyl-1-yl]benzonitrile) were evaluated in comparison with the established model of neurogenic inflammation in the meninges. Sumatriptan and donitriptan inhibited CGRP release as well as neurogenic inflammation. ASA, however, attenuated neurogenic inflammation, but not CGRP release, confirming the concept of prejunctional inhibition of CGRP release by 5-HT1B/1D receptors. This new model allows the further study of prejunctional pharmacology and mechanisms of neuropeptide release in the trigeminal vascular system, which might be crucial for the further development of potent, more effective anti-migraine drugs.
科研通智能强力驱动
Strongly Powered by AbleSci AI